[Experimental prevention of deep venous thrombosis with low-molecular-weight heparin using implantable infusion devices].
We studied the effect of a fractionated heparin, Dalteparine Sodium, on the prevention of thrombosis of veins of the superior vena cava system catheterized by implantable infusion devices. Forty-six patients with solid or lympho-proliferative tumors, whose clinical condition required installation of a such device, were successively included into the study in 1991. The anticoagulant was administered for one month following implantation at the dosage of 2,500 anti-Xa units per day. The development of deep vein thrombosis was investigated by systematic Doppler ultrasound before the first and third months and at 1 year. Three early (D9, D12 and D16) and asymptomatic thrombosis were diagnosed (6.5%). This rate, although clearly more favourable, was not significantly different (p = 0.254) from the rate of 15.2% previously reported in a group of 72 comparable patients, but who did not receive preventive treatment. These results demonstrate the necessity and feasibility of a randomized study on a larger number of patients testing several protocols, before concluding on the efficacy of this type of preventive treatment.
Pucheu
A
A
Service d'Oncologie, CHG, Brive.
Leduc
B
B
Sillet-Bach
I
I
Payen
C
C
Assaf
W
W
Pucheu
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D015918:Infusion Pumps, Implantable / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy; D011446:Prospective Studies; D013927:Thrombosis / Q000517:prevention & control*; D014683:Vena Cava, Superior
D000970:Antineoplastic Agents; D006495:Heparin, Low-Molecular-Weight
Essai de prévention des thromboses veineuses profondes sur dispositifs de perfusion implantables par une héparine de bas poids moléculaire.